How to Appeal a Wegovy Prior-Authorization Denial

By the PriorAuthAppeal editorial team · Sources cited · Independent of Novo Nordisk

Last reviewed 2026-05-06

Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management and has been since 2021 — yet insurance denials remain frustratingly common. If you just received a denial letter, you are not alone, and the denial is not the end of the road. This guide walks you through exactly why insurers deny Wegovy, what federal law says about your right to appeal, and how to build a letter that gives you the best realistic shot at reversal.

At a glance

• Generic name: semaglutide 2.4 mg weekly subcutaneous injection
• FDA approval year: 2021
• FDA indication: Chronic weight management in adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with at least one weight-related comorbid condition; also approved for adolescents age 12 and older with BMI at or above the 95th percentile
• Drug class: GLP-1 receptor agonist
• Manufacturer: Novo Nordisk
• Typical monthly cost without insurance: $1,300–$1,600
• Primary clinical trial: STEP 1 (Wilding et al., NEJM 2021) — 14.9% mean body weight reduction over 68 weeks in adults with obesity

What Wegovy is and what it is FDA-approved to treat

Wegovy is a prescription GLP-1 receptor agonist — meaning it mimics a naturally occurring gut hormone called glucagon-like peptide-1 — that suppresses appetite, slows how quickly the stomach empties, and improves glucose regulation. Novo Nordisk manufactures it as a once-weekly self-injection at a dose of 2.4 mg. It received FDA approval in June 2021 specifically for chronic weight management, making it one of the few obesity medications with a dedicated FDA approval for that purpose rather than a secondary label.

The distinction matters enormously for your appeal. Because Wegovy is FDA-approved for weight management, your physician is prescribing it on-label — not off-label. On-label denials are legally easier to challenge than off-label denials, because the FDA has already formally determined that the drug is safe and effective for the use your doctor is recommending. If, by contrast, you are receiving Wegovy primarily for its cardiovascular benefit and your BMI falls below the threshold in the FDA labeling, that portion of the claim may be treated as off-label by your insurer, which is a harder argument to win (though the SELECT trial evidence, discussed below, is meaningful supporting data).

At $1,300–$1,600 per month without coverage, this is not a medication most patients can self-pay indefinitely. Novo Nordisk does offer a savings card for commercially insured patients who qualify, but that program does not apply to Medicare or Medicaid beneficiaries. The stakes of a successful appeal are real.

How major US insurers decide whether to cover Wegovy

Coverage decisions for Wegovy are not uniform — every insurer applies its own clinical criteria, and within a single insurer, your specific plan product matters as much as the insurer's name on your card.

• UnitedHealthcare generally covers Wegovy when the patient meets BMI criteria plus a documented comorbidity, and requires evidence of participation in a structured lifestyle program for at least six months.
• Aetna typically requires patients to complete a step-therapy trial — meaning you must first try and fail a cheaper medication, often phentermine, before Wegovy will be authorized.
• Cigna requires documentation of a structured weight-loss program and applies a 5% body weight reduction benchmark at 12 weeks for reauthorization of ongoing coverage.
• Anthem / Elevance Health applies medical necessity criteria that vary by regional plan and product line.
• BCBS plans vary significantly by state and by whether you are on a commercial, marketplace, or employer plan.
• Kaiser Permanente has regional variation and often ties Wegovy coverage to participation in their integrated weight-management program.

Three categories of plans are far less likely to cover Wegovy regardless of clinical criteria: many employer-sponsored plans that have explicitly carved out anti-obesity medications, most Medicare Part D plans (which are barred from covering weight-loss drugs under federal statute — specifically Section 1860D-2(e)(2)(A) of the Medicare Modernization Act), and some state Medicaid programs depending on their formulary decisions. If your denial letter says "plan exclusion" or "benefit exclusion," read the section below on denial reasons carefully — that denial type has a different appeal path than a medical-necessity denial.

The most common reasons insurers deny Wegovy

Insurers most commonly deny Wegovy for one of seven specific reasons, and knowing which one applies to you is the first thing to check in your denial letter.

• BMI threshold not met. Most insurers require a BMI of at least 30, or at least 27 with a documented comorbid condition. If your BMI was recorded close to a threshold, measurement error or recent weight fluctuation could be the problem.
• Comorbidity not on the insurer's recognized list. Conditions like polycystic ovary syndrome (PCOS) or osteoarthritis are weight-related but are frequently excluded from insurer-recognized comorbidity lists, even though they are clinically relevant.
• Lifestyle modification documentation missing or incomplete. Insurers routinely deny claims when they cannot see evidence that the patient participated in a structured diet or exercise program — even when that participation happened in a primary-care setting and simply was not formally documented.
• Step-therapy requirement not completed. Your insurer may require you to try and fail one or more cheaper anti-obesity medications (phentermine, Saxenda, Contrave, or Qsymia) before Wegovy is authorized.
• Plan-level anti-obesity medication exclusion. Some employer-sponsored plans categorically exclude all obesity medications as a benefit design choice, and this is not a medical-necessity denial — it is a coverage design denial.
• Failure to demonstrate ≥5% weight loss at 12 weeks. This applies at reauthorization, not initial approval. Cigna and some other payers require measurable progress before renewing coverage.
• Off-label cardiovascular-benefit claim below BMI threshold. If a prescriber justified Wegovy primarily for cardiovascular risk reduction and the patient's BMI falls below the labeled thresholds, the insurer may treat the request as off-label.

How to address each denial reason

BMI threshold denial: Get your BMI verified with a calibrated in-office measurement, not a self-reported or at-home number. If your BMI is close to 27 with a comorbidity, make sure the comorbidity is clearly coded in your medical record using the ICD-10 code your insurer recognizes. Request the insurer's exact clinical criteria document — they are required to provide it.

Comorbidity not recognized: Ask your physician to document not just the diagnosis but its pathophysiologic relationship to obesity. PCOS, for example, is directly driven by adipose-tissue insulin resistance. A letter from your physician explaining why the condition meets the clinical definition of an obesity-related comorbidity — even if it is not on the insurer's named list — can move a denial into the "exception" category.

Missing lifestyle documentation: A formal letter from your primary-care physician, a dietitian, or a behavioral health provider summarizing the content of counseling sessions — with dates and specific interventions — can satisfy this requirement retroactively. This does not need to be a 6-month gym membership; a documented series of dietary counseling visits often qualifies.

Step-therapy denial: If you have previously tried phentermine, Saxenda, Contrave, or Qsymia — even years ago — gather records showing that trial and its outcome. If you have not tried any of those agents, your physician can document medical reasons why step-therapy is contraindicated (for example, phentermine is contraindicated in patients with certain cardiovascular conditions). That contraindication documentation frequently overrides the step-therapy requirement.

Plan exclusion denial: This is the hardest denial to appeal internally. Your first step is confirming whether this is truly a blanket exclusion or a formulary decision — they have different appeal rights. If it is a blanket employer-sponsored exclusion, your appeal rights under ERISA may be limited, but you can escalate to your HR department or benefits administrator to request a plan amendment, particularly if a treating physician documents medical necessity. An external review request under ACA Section 2719 is worth filing regardless.

Reauthorization / 5% weight-loss denial: Document the patient's actual weight trajectory with dated records, and ask the prescribing physician to note any factors — medication titration delays, illness, adherence challenges — that may have slowed early response. Clinical guidelines, including the AACE/ACE 2023 obesity guidelines, do not use 5% at 12 weeks as a universal efficacy threshold, and your physician can say so explicitly.

How Wegovy differs from other GLP-1 medications

Wegovy, Ozempic, Mounjaro, and Zepbound are all GLP-1 receptor agonists, but they are not interchangeable for insurance purposes — and that distinction can affect your appeal strategy.

Ozempic contains the same molecule as Wegovy — semaglutide — but it is FDA-approved specifically for type 2 diabetes management, not for weight loss. Prescribing Ozempic for weight management is an off-label use. Wegovy, by contrast, is the on-label obesity treatment. If your insurer denied Wegovy but has been covering Ozempic for a diabetes diagnosis, that inconsistency may be worth raising in your appeal.

Mounjaro and Zepbound (tirzepatide, from Eli Lilly) work on both GLP-1 and GIP receptors — a dual mechanism that produced roughly 20–22% weight loss in the SURMOUNT-1 trial. Zepbound is the weight-management-indicated version; Mounjaro is the diabetes-indicated version. The dual-agonist mechanism gives tirzepatide somewhat different pharmacology, which may matter if your physician believes one agent is medically preferable for you specifically.

For adolescents, Wegovy has a specific FDA approval and dedicated trial data from STEP TEENS (Weghuber et al., NEJM 2022), covering patients age 12–17. That is a meaningful differentiator if you are appealing on behalf of an adolescent patient — you can cite a named trial directly rather than relying on adult extrapolation.

The SELECT trial (Lincoff et al., NEJM 2023) found that semaglutide specifically reduced major adverse cardiovascular events by 20% in adults with established cardiovascular disease and overweight or obesity — evidence that is currently unique to semaglutide among approved GLP-1 agents for this cardiovascular indication. If cardiovascular risk reduction is a clinical driver of your prescription, cite SELECT by name.

Federal and state laws that protect your right to appeal

Three federal statutes are directly relevant to a Wegovy denial appeal.

ACA Section 2719 (45 CFR 147.136) requires all ACA-compliant marketplace and employer plans to offer both an internal appeal and an external independent review for any adverse benefit determination. External review is particularly powerful: an independent organization, not your insurer, makes the final call.

ERISA Section 503 (29 CFR 2560.503-1) governs employer-sponsored plans and requires that your plan provide a full and fair review, with access to the clinical criteria used to deny your claim. This regulation entitles you to request the specific plan documents, clinical coverage guidelines, and the credentials of the reviewing clinician — all of which are useful in building your appeal.

ACA Section 1557 prohibits discrimination in health programs receiving federal financial assistance. This statute has been cited in obesity-medication appeals arguing that blanket exclusions of anti-obesity medications have a discriminatory impact on patients with a diagnosed chronic condition. While courts have not uniformly accepted this argument, it adds a legal basis to appeals that go to external review.

Some states — including New York, Illinois, and Louisiana — have enacted their own obesity-treatment coverage mandates that go beyond federal requirements. Check your state insurance commissioner's website for state-specific protections that may apply to your plan.

What a strong appeal letter contains

A strong Wegovy appeal letter leads with clinical necessity and anchors every claim to your specific medical record.

• Your documented BMI with date of measurement and, if applicable, the specific ICD-10 codes for each recognized comorbidity.
• A citation to the FDA-approved indication — Wegovy was approved in 2021 for exactly the use being requested, which distinguishes it from an off-label request.
• Clinical trial evidence. The STEP 1 trial (Wilding et al., NEJM 2021) demonstrated 14.9% mean body weight reduction over 68 weeks. STEP 5 (Garvey et al., Nature Medicine 2022) demonstrated sustained weight loss at 104 weeks. If cardiovascular disease is present, SELECT (Lincoff et al., NEJM 2023) showed a 20% reduction in major adverse cardiovascular events.
• Guideline support. The AACE/ACE 2023 Comprehensive Clinical Practice Guidelines for Obesity and the ADA Standards of Care 2025 (Section 8) both support GLP-1 receptor agonists as first-line pharmacotherapy for patients meeting BMI criteria.
• Prior treatment history, including documented failure of lifestyle intervention alone and, if applicable, prior pharmacotherapy.
• A direct response to the specific denial reason stated in your denial letter. Do not write a generic medical-necessity letter — answer the insurer's stated objection point by point.
• A formal request for external independent review if the internal appeal fails, citing ACA Section 2719 by name.

Your prescribing physician must co-sign the letter. A letter from a specialist — an endocrinologist or bariatric medicine physician — carries more weight than one from a primary-care physician alone when the insurer's criteria require specialist documentation.

Timeline: what happens after you submit your appeal

Your insurer is legally required to respond to an internal appeal within 30 days for non-urgent prior-authorization requests (60 days for retrospective claims). Urgent or expedited appeals — situations your physician documents as medically urgent — must receive a response within 72 hours. Those timeframes are set by ACA Section 2719 and apply to all ACA-compliant plans.

If the internal appeal is denied, you have the right to request external independent review, typically within 4 months of the internal denial (exact deadlines vary by plan). The independent reviewer is a clinical organization with no financial relationship to your insurer. Approval rates at external review are meaningful — studies of external review outcomes consistently show that patients who reach this stage win reversal in roughly 40–50% of cases across all drug classes.

Keep copies of every document you submit, every letter you receive, and every phone call (with date, time, and representative name). If your external appeal is also denied, your remaining options include a state insurance commissioner complaint, an ERISA lawsuit if you are on an employer plan, or working with your physician to request a different medication your plan does cover.

Frequently asked questions about appealing a Wegovy denial

Does Medicare cover Wegovy?

Medicare Part D does not currently cover Wegovy or any other weight-loss drug, due to a federal exclusion under Section 1860D-2(e)(2)(A) of the Medicare Modernization Act — no appeal will change this under current law. Congress has proposed legislation called the Treat and Reduce Obesity Act that would lift this exclusion, but as of this writing it has not been enacted. Medicare Advantage plans are now permitted to cover obesity drugs as a supplemental benefit starting in 2024 and beyond, so check your specific Advantage plan's Evidence of Coverage document.

My BMI is 28 and I have PCOS — can I appeal?

A BMI of 28 with PCOS does meet the FDA-approved threshold (BMI ≥ 27 with at least one weight-related comorbidity), but your appeal depends on whether your insurer recognizes PCOS as a qualifying comorbidity. Many insurer coverage policies list only conditions like hypertension, type 2 diabetes, and dyslipidemia. Your physician should write a letter explaining the direct mechanistic relationship between adiposity and PCOS — including hyperinsulinemia and androgen excess — and argue for a medical-necessity exception. It is a harder appeal than a standard comorbidity, but not an unreasonable one.

What if my insurer says I need to try phentermine first?

Step-therapy requirements for Wegovy are common, particularly at Aetna, but they can be overridden with a documented contraindication or intolerance. Phentermine is contraindicated in patients with uncontrolled hypertension, coronary artery disease, hyperthyroidism, and several other conditions. If none of those contraindications apply, your physician can document that prior weight-management attempts (including other medications or structured programs) have failed, which some plans accept as sufficient step-therapy evidence even without a specific phentermine trial.

Can a teenager get Wegovy covered through insurance?

Wegovy has FDA approval for adolescents age 12 and older with a BMI at or above the 95th percentile, and the STEP TEENS trial (Weghuber et al., NEJM 2022) provides direct safety and efficacy data for this age group. Coverage decisions for adolescents follow the same insurer criteria as adults but should cite the pediatric FDA indication explicitly. If your insurer denies a pediatric Wegovy claim, the argument that this is an on-label, FDA-approved use in an FDA-approved population is strong.

What is the difference between an internal appeal and an external appeal?

An internal appeal goes back to your own insurance company for a second clinical review — a different reviewer, but still employed by or contracted with your insurer. An external appeal goes to an independent review organization that has no financial relationship to your insurer, and its decision is typically binding on the plan. You generally must exhaust internal appeals before requesting external review, though some urgent situations allow you to skip to external review. ACA Section 2719 guarantees you the right to external review for any ACA-compliant plan.

How long do I have to file an appeal?

You typically have 180 days from the date on your denial letter to file an internal appeal, though some plans set shorter deadlines — read your denial letter carefully for the exact date. For external review, deadlines are typically within four months of the final internal denial. Missing these deadlines can waive your appeal rights, so treat them as hard cutoffs.

Get a physician-ready appeal letter in 30 minutes

Building a complete, clinically grounded appeal letter is possible on your own using the guidance above — and everything on this page is free to use. If you want a faster path, PriorAuthAppeal.com offers a service ($59, with a money-back guarantee if your physician declines to sign) that generates a customized, physician-ready appeal letter based on your denial reason, diagnosis, and insurer. Whether you write the letter yourself or use a tool to draft it, the most important thing is to act before your deadline and to respond directly to whatever specific reason your insurer put